Why the study?
Does CV-4151 prevent collagen-induced ECG changes and cardiac arrest in a rat model of cardiac ischemia?
Does CV-4151 prevent collagen-induced ECG changes and cardiac arrest in a rat model of cardiac ischemia?
In a rat model, the thromboxane synthetase inhibitor CV-4151 attenuated collagen-induced ischemic ECG changes and cardiac arrest, suggesting potential utility in preventing TXA2-mediated cardiac ischemia.
Hypothesis-generating in rats for TXA2 inhibition; leaves open any role in human cardiac ischemia.
Ten weeks old male Sprague-Dawley rats were used. One mg/kg of a calfskin type III collagen was injected into a tail vein under pentobarbital anesthesia, and the electrocardiogram (ECG) was recorded via leads I, II and III for 10 min. Abnormal ECG patterns, i.e., ST-T changes and incidence of arrhythmia, were shown after collagen injection, and some rats suffered cardiac arrest. Oral administration of (E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid (CV-4151), a thromboxane synthetase inhibitor, at the dose of 10 mg/kg two hr before the collagen injection made the ST-T changes small, and it reduced the incidence of cardiac arrest. The effect of CV-4151 was greater than that of 30 mg/kg of ticlopidine with the same type of treatment. Neither CV-4151 nor ticlopidine had any affect on collagen-induced decreases in the blood platelet count. However, plasma thromboxane (TX) B2 level in the CV-4151-treated group was very low in comparison with those in both the control and ticlopidine-treated groups at 10 min after the collagen injection. These findings indicate that TXA2 may contribute, at least partly, to the collagen-induced ECG changes and indicate that CV-4151 might be a favorable agent for the prevention of TXA2-mediated cardiac ischemia.
No takes yet. Share an insight, caveat, or question.
MATSUMURA et al. (1986) studied this question.